Fri.Nov 03, 2023

article thumbnail

Moderna adjusts to changing outlook for COVID vaccine demand

Bio Pharma Dive

The company recorded a net loss in the third quarter as it “resizes” its manufacturing footprint, and now expects revenue to come in at low end of its previous guidance.

article thumbnail

Rapid rollout of NHS blood-thinning drugs has saved thousands of lives

Pharma Times

Since 2022, an estimated 17,000 strokes and 4,000 deaths have been prevented - News - PharmaTimes

Drugs 152
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

November brings new flurry of biotech layoffs

Bio Pharma Dive

Seres, Kronos Bio and Rani Therapeutics joined Sangamo in announcing job cuts, while private biotech LocanaBio revealed it's shutting down.

162
162
article thumbnail

Terremoto secures $175m in Series B to advance small molecule drugs

Pharmaceutical Technology

In May 2022, Terremoto raised $75m on Series A financing for its lysine-based covalency drug development platform.

Drugs 147
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Pfizer cuts 200 jobs at COVID drug, vaccine plant in Michigan amid $3.5B savings campaign

Fierce Pharma

Pfizer’s plunging COVID-19 product demand has spurred a companywide cost-cutting campaign, with nearly 200 jobs now on the chopping block in Michigan. | Pfizer is cutting roughly 200 positions at its Kalamazoo site following a review of demand for its COVID-19 vaccine and antiviral Comirnaty and Paxlovid.

article thumbnail

‘All-clear’ cancer referral patients at higher risk of subsequent cancer

Pharma Times

Over 63,000 cancer cases were diagnosed between one and five years after referral - News - PharmaTimes

130
130

More Trending

article thumbnail

Alvogen's bid to force FDA to approve generic to Bausch's Xifaxan shot down by federal court

Fierce Pharma

Bausch Health’s gastroenterology unit Salix Pharmaceuticals has chalked up a win in its long-running fight to fend off a generic to its irritable bowel syndrome diarrhea (IBD-D) med Xifaxan. | The D.C. federal court denied Alvogen's bid to force the FDA to grant full approval to its proposed Xifaxan generic. The agency previously gave the generic a tentative approval before some patents expire in 2029.

115
115
article thumbnail

Kronos downsizes workforce by 19% to funnel funds into cancer drugs

Pharmaceutical Technology

Kronos Bio joins other pharma companies in workforce reductions, cutting 19% of its employees to support clinical development.

article thumbnail

Study finds higher cancer rate in patients given ‘all clear’

pharmaphorum

Study finds higher cancer rate in patients given ‘all clear’ Phil.

114
114
article thumbnail

I-Mab and HI-Bio gain breakthrough therapy designation for PMN therapy

Pharmaceutical Technology

I-Mab and HI-Bio have received breakthrough therapy designation from the US FDA for the investigational CD38 antibody, felzartamab

Antibody 130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Scientists in the C-Suite: Attracting investors takes more than good science

pharmaphorum

Scientists in the C-Suite: Attracting investors takes more than good science Mike.

Scientist 111
article thumbnail

Eli Lilly reports net loss of $57.4m in Q3 2023 

Pharmaceutical Technology

Eli Lilly and Company has posted a net loss of $57.4m for Q3 2023 compared to a net income of $1.4bn in the same quarter last year.

130
130
article thumbnail

Moderna swings to loss as COVID sales slump

pharmaphorum

Moderna swings to loss as COVID sales slump Phil.

Sales 105
article thumbnail

Expanded use of oral blood thinners by NHS has saved “thousands of lives”

Pharmaceutical Technology

The rapid rollout of direct oral anticoagulants has prevented an estimated 17,000 strokes and 4,000 deaths, says the NHS.

130
130
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Championing Inclusivity During Disability Employment Awareness Month 2023

Intouch Solutions

In October 2023, we proudly observe National Disability Employment Awareness Month (NDEAM). EVERSANA INTOUCH used the opportunity to spotlight one of our remarkable employees, Emelia Patterson. Emelia embodies the spirit of diversity, inclusion, and innovation, making her a true asset to our EVERSANA INTOUCH family. Emelia Patterson, Account Director, is hard of hearing.

104
104
article thumbnail

The large amendment to Poland’s Reimbursement Act—disappointing, but not disastrous

Pharmaceutical Technology

The large amendment to Poland’s Reimbursement Act (Duża Nowelizacja Ustawy Refundacyjnej, DNUR) finally came into legal force on November 1, although a small number of its regulations will only come into force in 2024 and 2025.

article thumbnail

Lexeo files $100m IPO in tough listing environment

pharmaphorum

Lexeo files $100m IPO in tough listing environment Phil.

103
103
article thumbnail

The hot new tech transforming pharmaceuticals: Modular Real-Time communication

Pharmaceutical Technology

Getting shipments from factories to end users on time and in top condition is a major priority for pharma firms

130
130
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Interview: IQVIA's Liss Easy - from Disney to the drugs industry

Outsourcing Pharma

From Disney to the drug world, Liss Easy has had a fascinating journey to where she is now in her role as vice president and general manager of clinical operations at IQVIA.

Drugs 87
article thumbnail

Phathom scores two FDA wins for acid reflux drug after several setbacks  

Pharmaceutical Technology

The achievement for Phathom Pharmaceuticals comes after a period of delay and scrutiny by the FDA for Voquezna.

Drugs 130
article thumbnail

Is Your Hub Partner Missing the Therapeutic Area Expertise You Need?

Drug Channels

Today’s guest post comes from Greg Morris, Chief Strategy Officer at CareMetx. Greg highlights the value of therapeutic area expertise in enhancing the performance of hub services. He explains how CareMetx's hub used its experience in the retina space to improve a new brand-name product’s launch. To learn more about the impact of hub service on brand launch success, download CareMetx’s latest report: Patient Service Trends Point the Way to Better Hub/ Provider Partnerships.

article thumbnail

Innovative GLP1R-targeting drugs dominate type 2 diabetes pipeline

Pharmaceutical Technology

Driven by success of recent GLP1R-targeting drugs, there has been a surge in the number of active pipeline drugs addressing this target for type 2 diabetes.

Drugs 130
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Kronos sheds staff despite positive data for cancer drug

pharmaphorum

Kronos sheds staff despite positive data for cancer drug Phil.

Drugs 72
article thumbnail

Bayer and Broad Institute extend cancer therapy development programme

Pharmaceutical Technology

Bayer and the Broad Institute of MIT and Harvard have expanded their ten-year research partnership to further develop cancer treatments.

article thumbnail

Harmonizing next-gen MES with traditional approaches for smarter manufacturing

Fierce Pharma

Olivia Gannon, Associate Director of Global MES and Digital Execution Systems, Life Sciences Manufacturing, Cognizant, explores how a digitalization strategy harnessing the latest innovatio | Olivia Gannon, Global MES Service Line Lead at Cognizant, explores how a digitalization strategy harnessing the latest innovations in MES technologies can help streamline life science manufacturing.

article thumbnail

EC approves Gedeon Richter-Sumitomo’s RYEQO for endometriosis

Pharmaceutical Technology

The European Commission (EC) has approved Gedeon Richter and Sumitomo Pharma’s Type II Variation application for RYEQO for endometriosis.

130
130
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

New patent expiration for Novartis drug LEQVIO

Drug Patent Watch

Annual Drug Patent Expirations for LEQVIO Leqvio is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are seventeen patents protecting… The post New patent expiration for Novartis drug LEQVIO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59
article thumbnail

Oleclumab by AstraZeneca for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Pharmaceutical Technology

Oleclumab is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

article thumbnail

New patent expiration for Alnylam Pharms drug ONPATTRO

Drug Patent Watch

Annual Drug Patent Expirations for ONPATTRO Onpattro is a drug marketed by Alnylam Pharms Inc and is included in one NDA. It is available from one supplier. There are sixteen… The post New patent expiration for Alnylam Pharms drug ONPATTRO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 59
article thumbnail

Aspacytarabine hydrochloride by Ayala Pharmaceuticals for Myelodysplastic Syndrome: Likelihood of Approval

Pharmaceutical Technology

Aspacytarabine hydrochloride is under clinical development by Ayala Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.